Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
41 - 50of about 655 News
41 - 50of about 655 News
May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
READ MORE
April 27, 2021
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
“We’re optimistic for the future”
READ MORE
April 10, 2021
Not intended for U.S. and UK Media – Plenary Session at AACR Annual Meeting 2021:
Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma
READ MORE
April 06, 2021
Not intended for U.S. and UK Media
Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021
READ MORE
March 23, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Vitrakvi™ in Japan
READ MORE
March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021:
Bayer to further strengthen expertise and international profile of its Supervisory Board
READ MORE
March 10, 2021
Capital Markets Day 2021:
Bayer expects dynamic growth with higher profitability in the coming years and is accelerating its transformation
READ MORE
February 25, 2021
Fiscal 2020:
Bayer delivers robust performance despite pandemic – foundation laid for future growth
READ MORE
February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division
READ MORE
February 09, 2021
Not intended for U.S. and UK Media
Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes
READ MORE
41 - 50of about 655 News
41 - 50of about 655 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more